Published in BMC Microbiol on May 11, 2009
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
CRISPR-Cas9-mediated single-gene and gene family disruption in Trypanosoma cruzi. MBio (2014) 1.17
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
A rapid, efficient and economical method for generating leishmanial gene targeting constructs. Mol Biochem Parasitol (2010) 1.03
A high-throughput cloning system for reverse genetics in Trypanosoma cruzi. BMC Microbiol (2010) 0.97
CRISPR/Cas9-Induced Disruption of Paraflagellar Rod Protein 1 and 2 Genes in Trypanosoma cruzi Reveals Their Role in Flagellar Attachment. MBio (2015) 0.94
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase. Biochem J (2014) 0.87
A semantic problem solving environment for integrative parasite research: identification of intervention targets for Trypanosoma cruzi. PLoS Negl Trop Dis (2012) 0.81
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool. Bioengineered (2012) 0.79
Construction of three new Gateway® expression plasmids for Trypanosoma cruzi. Mem Inst Oswaldo Cruz (2014) 0.78
Knockout confirmation for Hurries: rapid genotype identification of Trypanosoma cruzi transfectants by polymerase chain reaction directly from liquid culture. Mem Inst Oswaldo Cruz (2014) 0.75
Plasmid vectors and molecular building blocks for the development of genetic manipulation tools for Trypanosoma cruzi. PLoS One (2013) 0.75
The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science (2005) 7.61
The trypanosomiases. Lancet (2003) 5.96
Control of Chagas disease. World Health Organ Tech Rep Ser (2002) 4.00
Double targeted gene replacement for creating null mutants. Proc Natl Acad Sci U S A (1991) 3.72
The Trypanosoma cruzi proteome. Science (2005) 2.63
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A (2008) 2.54
Nucleotide sequences provide evidence of genetic exchange among distantly related lineages of Trypanosoma cruzi. Proc Natl Acad Sci U S A (2001) 2.29
A shuttle vector which facilitates the expression of transfected genes in Trypanosoma cruzi and Leishmania. Nucleic Acids Res (1992) 1.99
Oligopeptidase B-dependent signaling mediates host cell invasion by Trypanosoma cruzi. EMBO J (1998) 1.84
The life cycle of Trypanosoma cruzi revisited. Int J Parasitol (2001) 1.58
Functional mapping of a trypanosome centromere by chromosome fragmentation identifies a 16-kb GC-rich transcriptional "strand-switch" domain as a major feature. Genome Res (2005) 1.47
Tests of cytoplasmic RNA interference (RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypanosoma cruzi. Mol Biochem Parasitol (2004) 1.40
Simple one-week method to construct gene-targeting vectors: application to production of human knockout cell lines. Biotechniques (2006) 1.36
Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol Microbiol (2008) 1.33
Targeting DHFR in parasitic protozoa. Drug Discov Today (2005) 1.28
Genetic manipulation of kinetoplastida. Parasitol Today (1999) 1.22
Integration of expression vectors into the ribosomal locus of Trypanosoma cruzi. Gene (2003) 1.16
Deletion of an immunodominant Trypanosoma cruzi surface glycoprotein disrupts flagellum-cell adhesion. J Cell Biol (1993) 1.13
LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. Infect Immun (2001) 1.12
Parameters controlling the rate of gene targeting frequency in the protozoan parasite Leishmania. Nucleic Acids Res (1997) 1.09
Polymerase chain reaction-based gene disruption in Trypanosoma brucei. Mol Biochem Parasitol (1997) 1.08
The origin of dihydroorotate dehydrogenase genes of kinetoplastids, with special reference to their biological significance and adaptation to anaerobic, parasitic conditions. J Mol Evol (2005) 1.06
The suppression of galactose metabolism in Trypanosoma cruzi epimastigotes causes changes in cell surface molecular architecture and cell morphology. Mol Biochem Parasitol (2006) 1.05
The interplay between folding-facilitating mechanisms in Trypanosoma cruzi endoplasmic reticulum. Mol Biol Cell (2003) 1.01
The Trypanosoma cruzi metacyclic-specific protein Met-III associates with the nucleolus and contains independent amino and carboxyl terminal targeting elements. Int J Parasitol (2006) 1.01
Intracellular growth and metacyclogenesis defects in Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele. Mol Microbiol (1999) 0.96
Effects of 3' untranslated and intergenic regions on gene expression in Trypanosoma cruzi. Mol Biochem Parasitol (1995) 0.90
Flagellar elongation induced by glucose limitation is preadaptive for Trypanosoma cruzi differentiation. Cell Motil Cytoskeleton (2000) 0.89
Cloning and expression of the dihydrofolate reductase-thymidylate synthase gene from Trypanosoma cruzi. Mol Biochem Parasitol (1994) 0.88
Genetic regulation of protein synthesis in trypanosomes. Curr Mol Med (2004) 0.87
Control of gene expression and genetic manipulation in the Trypanosomatidae. Genet Mol Res (2003) 0.86
The calmodulin-ubiquitin (CUB) genes of Trypanosoma cruzi are essential for parasite viability. Mol Biochem Parasitol (1996) 0.84
A transformation vector for stage-specific expression of heterologous genes in Trypanosoma cruzi epimastigotes. Parasitol Res (1997) 0.84
Trypanosoma cruzi: attenuation of virulence and protective immunogenicity after monoallelic disruption of the cub gene. Exp Parasitol (2007) 0.81
RNA interference as a genetic tool in trypanosomes. Methods Mol Biol (2008) 0.80
Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol (1997) 0.77
A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol Cell Proteomics (2005) 2.52
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis (2004) 1.79
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol (2006) 1.51
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics (2009) 1.42
Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol (2014) 1.42
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics (2005) 1.35
The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics (2009) 1.33
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol (2005) 1.33
New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis (2013) 1.23
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol (2009) 1.17
Chagas disease in rural areas of Chaco Province, Argentina: epidemiologic survey in humans, reservoirs, and vectors. Am J Trop Med Hyg (2004) 1.16
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis (2012) 1.05
Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol (2008) 1.05
Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J Immunol (2003) 1.02
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol (2010) 1.02
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol Biochem Parasitol (2003) 0.98
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine (2003) 0.96
Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clin Vaccine Immunol (2007) 0.95
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother (2005) 0.94
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur J Immunol (2007) 0.91
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol (2007) 0.90
Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun (2004) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Protective immunity against Trypanosoma cruzi. Mem Inst Oswaldo Cruz (2009) 0.88
TcruziDB: an integrated Trypanosoma cruzi genome resource. Nucleic Acids Res (2004) 0.88
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease. Antimicrob Agents Chemother (2010) 0.86
Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect (2010) 0.85
Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report. Invest Clin (2011) 0.84
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling. Infect Immun (2010) 0.83
Multidimensional analysis of the insoluble sub-proteome of Oceanobacillus iheyensis HTE831, an alkaliphilic and halotolerant deep-sea bacterium isolated from the Iheya ridge. Proteomics (2007) 0.82
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
Transgenic parasites accelerate drug discovery. Trends Parasitol (2012) 0.80
Multidimensional proteomic analysis of the soluble subproteome of the emerging nosocomial pathogen Ochrobactrum anthropi. J Proteome Res (2006) 0.80
A combined shotgun and multidimensional proteomic analysis of the insoluble subproteome of the obligate thermophile, Geobacillus thermoleovorans T80. J Proteome Res (2006) 0.78
Trypanosoma cruzi: infectivity modulation of a clone after passages through different hosts. Exp Parasitol (2006) 0.77
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem (2010) 0.77
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives. J Med Chem (2007) 0.76
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease. Eur J Med Chem (2007) 0.75